Ignite Creation Date:
2024-05-06 @ 1:43 PM
Last Modification Date:
2024-10-26 @ 1:18 PM
Study NCT ID:
NCT04101708
Status:
UNKNOWN
Last Update Posted:
2019-09-24
First Post:
2019-09-23
Brief Title:
A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for HP Eradication in Elderly Patients
Sponsor:
Shandong University
Organization:
Shandong University
Study Overview
Official Title:
A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for HP Eradication in Elderly Patients
Status:
UNKNOWN
Status Verified Date:
2019-09
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess and compare the effectiveness and safety of high-dose dual therapy and half-dose clarithromycin-containing bismuth quadruple therapy in elderly patients for eradicating Hpylori
Detailed Description:
Helicobacter pylori plays an important role in many diseases such as peptic ulcer disease and MALT lymphomas And the prevalence of H pylori remains high in developing countriesincluding China
Clarithromycin-containing bismuth quadruple therapy has been recommended as the first-line therapy for H pylori infection in China However its expensive cost and high antibiotic-related adverse reactions are always haunting us In 2018a research from NanFang hospitalChinarevealed that 250mg clarithromycin is as effective as 500mg clarithromycinat the same timecauses less adverse reactions On the othe handprevious studies reported a new regimen called large dose dual therapygenerally contains a PPI and amoxicillinwhile some of them have achieved very good resultsespecially in Taiwan
However specific data on anti-Hpylori treatments in elderly people are very lackingSowe aim to assess and compare the effectiveness and tolerability of high-dose dual therapy and half-dose clarithromycin-containing bismuth quadruple therapy in elderly patientsConsidering the difference of drug metabolism between eldery and young peoplea satisfactory result may be obtained
Clarithromycin-containing bismuth quadruple therapy has been recommended as the first-line therapy for H pylori infection in China However its expensive cost and high antibiotic-related adverse reactions are always haunting us In 2018a research from NanFang hospitalChinarevealed that 250mg clarithromycin is as effective as 500mg clarithromycinat the same timecauses less adverse reactions On the othe handprevious studies reported a new regimen called large dose dual therapygenerally contains a PPI and amoxicillinwhile some of them have achieved very good resultsespecially in Taiwan
However specific data on anti-Hpylori treatments in elderly people are very lackingSowe aim to assess and compare the effectiveness and tolerability of high-dose dual therapy and half-dose clarithromycin-containing bismuth quadruple therapy in elderly patientsConsidering the difference of drug metabolism between eldery and young peoplea satisfactory result may be obtained
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None